Flow Neuroscience Reaches 100,000 Patient Milestone for At-Home Depression Treatment
Summary
Flow Neuroscience announced that its at-home transcranial direct current stimulation device for depression has been used by over 100,000 patients. The device delivers mild electrical stimulation to the dorsolateral prefrontal cortex, a brain area associated with mood regulation. Flow's treatment combines the tDCS device with a behavioral therapy app delivered through a smartphone.
Why it matters
This milestone demonstrates the scalability and accessibility of at-home neurostimulation for treating depression, particularly in regions where access to traditional mental health services is limited. Flow's combination of hardware and software represents a digital therapeutics approach that could complement or provide an alternative to pharmacological treatments. The large patient experience provides valuable real-world effectiveness and safety data for tDCS in depression.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial